Tandem Diabetes Care Appoints New Executive Vice President of Strategy and Corporate Development

Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a leading insulin delivery and diabetes technology company, today announced the appointment of Elizabeth Gasser as its new Executive Vice President, Strategy and Corporate Development. Gasser will lead all activities related to evolving and implementing the Company’s long-term strategic direction in alignment with its mission to improve the lives of people with diabetes.

"Liz has been an instrumental consultant in recent months, providing insights to help shape and define our longer-term strategic business plan, which positions us to lead in insulin therapy management by building a robust ecosystem and portfolio of data-driven products and services,” said John Sheridan, president and CEO of Tandem Diabetes Care. "We are confident in her ability to lead in the implementation of these strategies as part of the executive management team and help drive Tandem’s continued success.”

"Tandem’s strategic plan focuses on providing the world’s best insulin delivery systems, building relationships and expanding the value we provide our customers, healthcare providers and payors, and using data in new ways to deliver revolutionary insights and experiences,” said Gasser. "There’s meaningful, long-term opportunity for Tandem and I look forward to contributing in my new role.”

Before becoming an independent advisor in 2017, Gasser led the corporate strategy function at Qualcomm Incorporated, working with the Executive Team and general managers of its various lines of business. During her 11 years at Qualcomm, she also led strategy and corporate development for its emerging business portfolio and the Qualcomm Internet Services division. Prior to Qualcomm, Gasser spent five years at Openwave Systems, the world’s leading mobile browser provider at the time, where she held strategy, product and market research roles. Before Openwave, she worked as a strategy consultant in both London and San Francisco. Gasser holds a BA and MA in Economics from Cambridge University, UK. She also serves as the Board Chair for Athena, a non-profit organization focused on professional advancement for women in STEM fields.

About Tandem Diabetes Care, Inc.

Tandem Diabetes Care, Inc. (www.tandemdiabetes.com) is a medical device company dedicated to improving the lives of people with diabetes through relentless innovation and revolutionary customer experience. The Company takes an innovative, user-centric approach to the design, development and commercialization of products for people with diabetes who use insulin. Tandem manufactures and sells the t:slim X2 insulin pump with Control-IQ technology. The t:slim X2 pump is capable of remote feature updates using a personal computer. Tandem is based in San Diego, California.

Follow Tandem Diabetes Care on Twitter @tandemdiabetes, use #tslimX2 and $TNDM.

Follow Tandem Diabetes Care on Facebook at www.facebook.com/TandemDiabetes.
Follow Tandem Diabetes Care on LinkedIn at www.linkedin.com/company/TandemDiabetes.

Tandem Diabetes Care is a registered trademark, and t:slim X2 and Control-IQ are trademarks of Tandem Diabetes Care, Inc. All other third-party marks are the property of their respective owners.

Forward Looking Statement

This press release contains "forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that concern matters that involve risks and uncertainties that could cause actual results to differ materially from those anticipated or projected in the forward-looking statements. These forward-looking statements relate to, among other things, the anticipated future growth of the Company and the Company’s abilities to define and implement its longer-term strategic business plan. These statements are subject to numerous risks and uncertainties, including our ability to obtain regulatory approval for new products and products under development and the timing of any such approvals; market acceptance of the Company’s existing products and products under development by physicians and people with diabetes; the Company’s ability to meet increasing operational and infrastructure requirements from higher customer interest and a larger base of existing customers; as well as other risks identified in our most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q, and other documents that we file with the Securities and Exchange Commission. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this release. Tandem undertakes no obligation to update or review any forward-looking statement in this press release because of new information, future events or other factors.

View source version on businesswire.com: https://www.businesswire.com/news/home/20200109005724/en/